MacroGenics, Inc. (MGNX) - Price-to-Projected Revenue Ratio

Graphic logo of MacroGenics Inc. (MGNX)

Biotech development depends on targeted therapy trial results, which determine the market split for MacroGenics, Inc. (MGNX). The forward P/S ratio reflects consensus dynamics, where the value 0.90 represents the current metric. Market capitalization relies on Margenza sales and royalties from oncology centers. Meanwhile, high R&D expenditures render operating profit volatile, despite having an approved drug.

macrogenics.com - MGNX Forward P/S Multiple (period 07/04/2022 - 11/13/2026)

Comprehensive metric breakdowns and analytics for MacroGenics Inc. (MGNX)

- market price and analyst price targets:
Price Chart MacroGenics|MGNX - Fair Value Consensus
- market capitalization indicators:
Market Value MacroGenics Inc.|MGNX - Real Price to Acquire Entire Company
- book value of equity indicators:
Book Value per Share MacroGenics|MGNX - Book Capitalization|Market Capitalization to Book Value Ratio macrogenics.com|MGNX - Cumulative Company Assets
- debt level and financial liquidity data:
Debt to Equity MacroGenics, Inc.|MGNX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity MacroGenics, Inc.|MGNX - Company Cumulative Debt|Debts to Book Capitalization MacroGenics Inc.|MGNX - Long-Term Indebtedness|Company Short-Term Debts MacroGenics|Quick Liquidity macrogenics.com
- financial results and valuation multiples details:
MGNX - Company Profit|Projected Future Earnings MacroGenics, Inc.|MGNX - Business Payback Period|Forward P/E Multiple MacroGenics Corp|MGNX - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MacroGenics Inc.|MGNX - Operating income before deduction of amortization|Net earnings per share for the last 12 months MacroGenics|MGNX - Earnings per share for the trailing year|Quarterly EPS earnings growth macrogenics.com|MGNX - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year MacroGenics, Inc.
- total revenue and sales volume data:
MGNX - Company Sales Volume|Projected Sales Volume MacroGenics|MGNX - Market Cap to Revenue|Forward Price-to-Revenue Multiple MacroGenics Inc.
Initial company analysis:MacroGenics MGNX
Original product of MacroGenics, Inc.

Institutional capital utilizes this indicator to assess the overpayment for the future growth rates of MacroGenics, Inc. (MGNX) amid geopolitical risks affecting raw material supplies and patent protection. The expected P/S ratio is calculated as the ratio of current market capitalization to projected revenue, allowing an analysis of the chart to determine the fairness of the asset's market value relative to its potential cash flows.

Main competitors

Price-to-Projected Revenue Ratio Olema OLMA|Forward Price to Sales PBYI|GLSI - Price-to-Projected Revenue Ratio|Zentalis Pharma (ZNTL) - Forward Price-to-Revenue Multiple|PSTV: Forward P/S Multiple|Processa Pharmaceuticals, Inc. (PCSA) - Forward P/S Multiple|EGRX (Eagle Pharmaceuticals Inc.) - Forward P/S Multiple